FDA Approves Spinal Cord Stimulation (SCS) System for Diabetic Peripheral Neuropathy

On January 26, 2023, it was announced that the FDA (US Food and Drug Administration) had approved Abbott’s Proclaim XR spinal cord stimulation (SCS) system for treating painful diabetic peripheral neuropathy.

Approved in 2019 for the treatment of chronic pain, the Proclaim XR SCS system provides stimulation at low doses and has been shown to relieve pain in patients with diabetic peripheral neuropathy.

After a successful trial period applied with a minimally invasive method, patients are implanted with the Proclaim XR SCS system. Patients will have the ability to control their treatment via an Apple device. People receiving treatment from the Proclaim XR SCS system can communicate with the doctor using the NeuroSphere Virtual Clinic, an application of Abbott, and their treatment can be adjusted remotely. The Proclaim XR SCS system battery can operate for up to 10 years at low dose settings.